In addition, four lung adenocarcinoma RDAA+ patients received crizotinib therapy (another ALK inhibitor, 250–500 mg /day for 4 weeks, Fig. 5b and Supplementary Fig. 5, a), three out of four patients achieved objective response: one complete response (CR, patient #01, Fig. 5b) and two partial response (PR, patients #02 and #04). Here, ALK is linked to lung adenocarcinoma.